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Scomplications encountered with current endovascular techniques. The results obtained
seem promising. A larger study is ongoing.
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THEMULTILAYER FLOWMODULATOR STENT FOR THE TREATMENT
OF THORACO ABDOMINAL AND ABDOMINAL AORTIC ANEURYSMS.
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Background: Thoraco Abdominal Aortic Aneurysms (TAAA) and Abdominal Aortic
Aneurysms (AAA) are traditionally treated surgically, but more and more by inter-
ventional procedures (endografts, fenestrated, branched grafts, chimney techniques).
We used a new concept of stent, the Multilayer Stent Flow Modulator (M.F.M) to treat
these aneurysms (A) and try to avoid some major complications.
Methods: This selfexpandable M.F.M is a 3 D braided tube made of several inter-
connected layers without any covering. We will explain and demonstrate the key
principles of the stent leading to thrombosis, shrinkage of the A, eliminating the risk of
rupture. Moreover, this M.F.M preserves the collateral branches allowing the possi-
bility to cover any artery without compromising the ﬂow (renal, digestive arteries,
supra aortic vessels.).
Results: 10 TAAA, 8 AAA (7 extended to both iliac arteries) treated with MFM
in very high risk patients. 53 MFM implanted (1 to 5 per pt). o Technical success:
100% o At 30 days: no neurological complication, branch patency 100%, no death o
During the follow up we had 3 deaths not device related. CT scan control performed
at 1, 3, 6, 12, 18 months with calculation of A. Diameters and Volumes. o All
collateral branches remain patent and we observed a progressive thrombosis
and shrinkage of the aneurysmal sac depending on the size of the collaterals.
Some patients developed a thrombus after 1 month, some after 6 months and some-
even after 18 months. A signiﬁcant mean diameter reduction was observed between
baseline and 6 months: 17,25 mm reduction for the transversal diameter, 13,83 mm for
the antero posterior diameter in the TAAA group. Overtime the ratio thrombus volume
/ Total Volume is increasing and the ratio Residual Flow Volume / Total Volume is
decreasing. The problems of thrombosis, shrinkage and volume reduction of the
aneurysmal sac will be discussed. The complications rates with M.F.M appear lower
in comparison with current endovascular techniques, and with surgery.
Conclusions: The M.F.M represents an alternative to current devices to treat TAAA
and AAA. It is a safe procedure with a low complication rate. The ﬁrst results are
promising. A larger study is ongoing.
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Background: Extensive acute deep venous thrombosis (DVT) responds favorably to
catheter directed thrombolysis (CDT). Argatroban is an effective parenteral direct
thrombin inhibitor which makes it an attractive drug for DVT treatment. There is
a paucity of data on the utilization of argatroban in combination with tPA for extensive
DVT.
Methods: 35 patients with extensive DVT involving the femoropopliteal and
iliac veins underwent PEVI. DVT was bilateral in 24 patients. A 6-8 F sheath was
placed in each popliteal vein under ultrasound guidance. DVT had developed within
10 days of major surgery in 7 patients. For maceration of the clot balloon venoplasty
was performed in all. Subsequently an infusion catheter was placed through the
popliteal sheath(s) and tPA delivered at 1mg/hr for 20-24 hours for unilateral DVT
and at 0.75 mg/hr through each infusion catheter for bilateral involvement. For
unilateral DVT, argatroban was given at 0.5 -1 mcg/kg/min through the side port of
the sheath and for bilateral DVT it was given at 0.3- 0.75 mcg/kg/min. PTT was kept
between 50-90 seconds. Every 3 hours the PTT was checked if there was a change in
the Argatroban dose. It was checked every 12 hours if the PTT had remained within
the therapeutic range. Follow-up venography was performed between 20- 30 hours
after PEVI.
Results: With the above regimen there were no bleeding complications even in the 7
patients with recent surgery. Complete or signiﬁcant resolution of thrombus was noted
in 32patients (91%). In 3 patients who previously had occlusive thrombus within their
IVC ﬁlter, the iliac and femoropopliteal DVT had resolved, however some degree of
thrombus in the IVC ﬁlter persisted. These were treated with further thrombectomy
and the procedure terminated at that time with removal of the sheaths.
Conclusions: CDT using a combination of low dose argatroban and tPA is highly
effective and safe in the treatment of massive diffuse DVT. The unacceptably high
rates of bleeding previously reported are not applicable to the contemporary era. A
synergistic effect exists between argatroban and tPA which make them an ideal
anticoagulant- thrombolytic combination for CDT.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-517
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Background: The current recommendation for the treatment of deep venous throm-
bosis (DVT) is at least 5 days of parenteral anticoagulation with a minimum of 24
hours of overlap with a vitamin K antagonist at a therapeutic INR. It has been well
established that percutaneous endovenous intervention(PEVI) reduces the sequelae of
DVT by early removal of thrombus. The efﬁcacy and safety of novel anticoagulants
rivaroxaban and dabigatran following PEVI has not been investigated.
Methods: 93 patients with femoropopliteal , iliac , upper extremity and internal
jugular DVT who had undergone PEVI underwent initiation of dabigatran (34
patients) or rivaroxaban (59 patients) within 2 hours after their procedure. No
parenteral anticoagulation was given when oral anticoagulants were started. The mean
follow up was 183 months. Aspirin at 81mg daily was given to 18 patients who had
received an endovenous stent and was continued for 1 month. The patients were
evaluated for recurrent venous thromboembolic (VTE) disease and bleeding during
the follow- up period.
Results: There was no bleeding or recurrent VTE in any patient. Two patients could
not tolerate dabigatran due to gastrointestinal side effects. The mean duration of
parenteral treatment was 315 hours. Enoxaparin was the parenteral anticoagulant in
32 patients and unfractionated heparin in the remainder. The mean duration of
hospitalization was 295 hours. At follow-up 3 patients died due to cancer.
Conclusions: In patients undergoing PEVI, the duration of safe and effective
parenteral anticoagulation is less than the traditionally accepted minimum of 5 days.
Initiation of rivaroxaban or dabigatran soon after PEVI promotes early discharge and
obviates the inconveniences associated with regulation of INR.
TCT-518
One-Year Results of the Multi-layer Flow Modulator Stent in the Management of
Thoracoabdominal Aortic Aneurysms.
Sherif Sultan1, Niamh Hynes1
1Western Vascular Institute, Galway, Ireland
Background: We present the ﬁrst 55 cases of MFM implanted under indication for
use to treat aortic disease. All were done on compassionate basis, in 11 countries.
Primary Endpoints are Freedom from Rupture and Aneurysm-related Death.
Methods: They were 31 Crawford Thoraco-abdominal (8 Type I, 3 Type II, 9 Type
III, and 11 Type IV), 7 arch, 3 abdominal, 8 suprarenal aortic aneurysms and 6 type B
dissections. Mean age of 64.5 years +/- 18years; mean aneurysm diameter was
6.04cm+/-1.66cm (Median 5.76cm). Mean number of side branches covered was 3.7
per case (median 4, range 0-6). Total 108 stents used, mean of 1.96 MFM per
case.(Median 2, range 1-5)
Results: One-year Aneurysm-related survival was 93.7% (SE+/-4.44%). No rupture
occurred. Technical success was 98.2%. One-year all-cause survival was 84.8%
(SE+/-6.25%). There was no paraplegia. No peri-operative visceral insult. At 12
months all 202 side branches were patent. No stent fractures. One-year intervention-
free survival was 92.4% (SE+/-5.09%) At six months mean rate of sac volume
increase was 0.36% per month. At twelve months the rate of increase had slowed to
0.28% per month. The ratio of thrombus to total volume stayed almost constant over
the 12 months at 0.48, while the ratio of ﬂow to total volume fell from 0.21 to 0.12 at
12 months.
Conclusions: Increasing sac size did not herald rupture. MFM implantation instigates
a process of aortic remodeling involving initial thrombus deposition, which slowed
between six and twelve months .The MFM was not associated with loss of native side
branches.
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Background: To achieve successful revascularization is important for wound healing
in critical limb ischemia (CLI) with tissue loss following endovascular therapy (EVT).
However, we sometimes experience failure to achieve wound healing even after
successful EVT. We investigated the relationship between wound healing and
successful revascularization according to wound types.
Methods: Between April 2007 and April 2012, 171 CLI patients (204 limbs) clas-
siﬁed to Rutherford 5 or 6 were treated by EVT in our institute. In these limbs, 199
individual wounds exited on foot and were evaluated wound healing rates and time to
healing according to their wound types with and without successful revascularization.
Wound types were divided into three groups, group T (Toe wound, n¼128), group Hacts/POSTER/Endovascular Intervention B157
